<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of bis(7)-<z:chebi fb="0" ids="45980">tacrine</z:chebi>, a novel <z:chebi fb="0" ids="38462">acetylcholinesterase inhibitor</z:chebi>, on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were investigated in primary cerebral cortical astrocytes of mice </plain></SENT>
<SENT sid="1" pm="."><plain>Following a 6 h in vitro ischemic incubation of the cultures, a marked decrease in the percentage of viable cells was observed by <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) release assay </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, using <z:chebi fb="0" ids="51232">bisbenzimide</z:chebi> staining, we determined that approximately 65% of the cells underwent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with bis(7)-<z:chebi fb="0" ids="45980">tacrine</z:chebi> (1-10 nM) during ischemic incubation effectively inhibited the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, as demonstrated by morphological and biochemical tests </plain></SENT>
<SENT sid="4" pm="."><plain>Our results demonstrated that bis(7)-<z:chebi fb="0" ids="45980">tacrine</z:chebi> could protect astrocytes against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced cell injury, indicating that the drug might be beneficial for the treatment of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, in addition to <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
</text></document>